RECURRENT MALIGNANT GLIOMA

This study tests a drug called ivosidenib (AG-120) in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have come back or not responded to standard treatment. The drug works by blocking a faulty signal that helps cancer grow. The main goal i…

This study tested a drug called larotrectinib in children and young adults (ages 1 to 21) with advanced or returning cancers that have a specific genetic change called an NTRK fusion. The goal was to see if the drug could shrink tumors or stop them from growing. The study include…

This early-stage study tests a new treatment for people with malignant glioma that has returned or not responded to standard therapy. Doctors take a patient's own immune cells (T cells), add a special gene to help them recognize and attack the tumor, and infuse them back. The mai…

This study tests whether pembrolizumab, an immunotherapy drug that helps the immune system fight cancer, can shrink or stop the growth of recurrent malignant glioma in 27 patients. The cancer must have returned after prior treatments like radiation and chemotherapy. The goal is t…

This study tests a drug called selpercatinib (LOXO-292) in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change in the RET gene. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients who…

This study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had come back or were not responding to treatment. The drug targets cancers with specific changes in FGFR genes. The main goal was to see if the drug could shrink tumors. About 2…

This early-phase study tests a new type of immune cell therapy (CAR T cells) designed to target a protein called MMP2 found on glioblastoma brain tumors that have returned or worsened. The main goals are to find the safest dose and understand side effects. About 19 participants w…

This study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…

This study tests the drug tipifarnib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers have a specific change in the HRAS gene. The goal is to see if tipifarnib can shrink or stop the growth of these hard-to-treat cancers. Parti…

This early-phase study tests a new approach for people with high-grade gliomas (aggressive brain tumors) that have come back after previous treatment. Researchers place genetically modified neural stem cells directly into the brain tumor to make it more sensitive to the chemother…

This study tests a new type of MRI that looks at sodium and other signals in the brain to get a clearer picture of tumors. It includes healthy volunteers and people with brain tumors (glioma) that are new or have returned. The goal is to improve how doctors detect, understand, an…

This study is observing 1000 adults with recurrent malignant gliomas (aggressive brain tumors) to see how they respond to chemotherapy and targeted therapy. Researchers are tracking survival and tumor progression over time. The goal is to gather real-world data to guide future tr…